Albany Molecular Research, Inc. (AMRI) announced that it along with sanofi-aventis US LLC, has filed a motion for a preliminary injunction in the United States District Court for the District of New Jersey seeking to enjoin Dr Reddy’s Laboratories, Ltd. and Dr Reddy’s Laboratories, Inc. (Dr. Reddy’s) from the commercial distribution of generic versions of Allegra-D 24 Hour (fexofenadine HCl 180 mg and pseudoephedrine HCl 240 mg) extended-release tablets in the US This action is in response to the March 17, 2010 approval of Dr Reddy’s generic version of Allegra-D 24 Hour by the FDA.

In September 2009, AMRI filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr Reddy’s for infringement of one of AMRI’s patents related to the manufacturing process for the active ingredient in Allegra, Allegra-D 12, and Allegra-D 24 Hour, which issued in 2008. Sanofi-aventis US is now joining AMRI in this lawsuit.

Regardless of the outcome of the preliminary injunction motion, AMRI will continue to forcefully and vigorously defend its intellectual property.

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life.